Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roy Jones

Vascular Surgery Tyler, TX Medical Doctor

NPI 1245650183 CMS profile 2782694

619 S Fleishel Ave Ste 203, Tyler, TX 75701

Open in the dashboard

General payments

$43,347

405 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Roy Jones of Tyler, TX is reported in the CMS Open Payments database as having received $43,347 across 405 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,491 92
2024 General $14,495 81
2023 General $2,622 54
2022 General $4,318 74
2021 General $1,859 39
2020 General $1,531 42
2019 General $2,032 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roy Jones
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Roy Jones were reported at $16,491. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Roy Jones Vascular Surgery median Middle half National median
2019 $2,032 $796 $226–$2,363 $163
2020 $1,531 $348 $118–$1,110 $114
2021 $1,859 $471 $158–$1,421 $132
2022 $4,318 $725 $222–$2,183 $149
2023 $2,622 $836 $257–$2,440 $160
2024 $14,495 $909 $252–$2,619 $164
2025 $16,491 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $14,329 33 payments
  2. Medtronic, Inc. $11,768 36 payments
  3. Silk Road Medical, Inc. $4,046 53 payments
  4. Medtronic Vascular, Inc. $2,095 26 payments
  5. Inari Medical, Inc. $1,748 33 payments
  6. Boston Scientific Corporation $1,496 53 payments
  7. W. L. Gore & Associates, Inc. $1,442 40 payments
  8. Shockwave Medical, Inc $1,185 22 payments
  9. Philips Electronics North America Corporation $1,172 11 payments
  10. Cook Medical LLC $1,011 36 payments
  11. Other $3,055 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,535 374 payments
  2. Travel and Lodging $15,112 26 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,600 4 payments
  4. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. Indigo System $14,162 31 payments
  2. ENDURANT IIS $11,398 33 payments
  3. ENROUTE Transcarotid Stent $3,869 49 payments
  4. ENROUTE Transcarotid Neuroprotection System $3,869 49 payments
  5. FLOWTRIEVER CATHETER, S $1,941 34 payments
  6. CT THROMBECTOMY SYSTEM KIT $1,555 32 payments
  7. HawkOne $1,175 10 payments
  8. Endurant $820 15 payments
  9. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $758 8 payments
  10. Peripheral Orbital Atherectomy System $714 5 payments
  11. Other $9,802 252 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

475

Median for Vascular Surgery: 122

Drug cost

$48,133

Median for Vascular Surgery: $14,135

Branded share of claims

56.8%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 29 $24,612
Eliquis Apixaban Brand 27 $15,584
Cilostazol Generic 189 $5,436
Clopidogrel Clopidogrel Bisulfate Brand 126 $1,303
Bupropion Hcl Sr Bupropion Hcl Brand 26 $521
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 62 $430
Gabapentin Generic 16 $246

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 130 billing codes

Paid by Medicare

$181,512

Medicare's payments for the services billed

Medicare patients

433

Average age 75

Services billed

1,610

198 women, 235 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 53%
Chronic kidney disease 45%
Diabetes 44%
Heart failure 36%
COPD 36%
Atrial fibrillation 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

405 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record